IP Library Granted Patent US 12,336,964
Granted Patent B2
US 12,336,964 · App. 18/775,531 · Granted Jun 24, 2025

Glass containers for storing pharmaceutical compositions

Inventors: Connor Thomas O'Malley (Painted Post, NY); Sinue Gomez-Mower (Corning, NY); Weirong Jiang (Sarasota, FL); Joseph Michael Matusick (Corning, NY); Christie Leigh McCarthy (Painted Post, NY); Steven Edward DeMartino (Painted Post, NY); John Stephen Peanasky (Big Flats, NY); Shivani Rao Polasani (Horseheads, NY); James Ernest Webb (Corning, NY); Michael Clement Ruotolo, Jr. (Corning, NY); Bryan James Musk (Williamstown, NJ); Jared Seaman Aaldenberg (Corning, NY); Eric Lewis Allington (Campbell, NY); Douglas Miles Noni, Jr. (Horseheads, NY); Amber Leigh Tremper (Painted Post, NY); Kristen Dae Waight (Lindley, NY); Kevin Patrick McNelis (Elmira, NY); Patrick Joseph Cimo (Corning, NY); Christy Lynn Chapman (Painted Post, NY); Robert Anthony Schaut (Horseheads, NY); Adam Robert Sarafian (Corning, NY)
Assignee: Corning Incorporated
A61J1/1468B65D23/0821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,336,964
App. No.
18/775,531
Filed
Jul 17, 2024
Granted
Jun 24, 2025
Kind
B2
Art Unit
3736
USPC
206/438
Abstract

Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter di of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness T i that is less than or equal to 0.85*s 1 , wherein s 1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Claims (32)

1. A glass pharmaceutical vial comprising:

a glass body comprising a sidewall enclosing an interior volume and an outer diameter D;

a shoulder extending from the sidewall; and

a neck extending from the shoulder;

wherein:

the outer diameter D of the glass body is greater than or equal to 84% and less than or equal to 116% of a diameter d 1 of a glass vial of size designation X as defined by ISO 8362-1:2018, wherein X is a smallest size designation of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R, as defined by ISO 8362-1:2018, for which 116% of the diameter d 1 is greater than or equal to D;

the sidewall of the glass pharmaceutical vial comprises an average wall thickness T i that is less than or equal to 0.85*s 1 , wherein s 1 is a wall thickness of the glass vial of size designation X as defined by ISO 8362-1:2018; and

the glass pharmaceutical vial further comprises a flange extending from the neck, the flange having a reduced glass volume relative to a glass volume of a flange of the glass vial of size designation X as defined by ISO 8362-1:2018.

2. The glass pharmaceutical vial of claim 1 , wherein the flange comprises:

an underside surface extending from the neck; and

an outer surface extending from the underside surface and being radially recessed inwardly thereby defining a cutout portion of the flange.

3. The glass pharmaceutical vial of claim 2 , wherein the cutout portion of the flange correlates to a reduction in a mass of glass used to make the glass pharmaceutical vial of greater than or equal to 5%.

4. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in a mass of glass used to make the glass pharmaceutical vial of greater than or equal to 10%.

5. The glass pharmaceutical vial of claim 4 , wherein the cutout portion of the flange correlates to a further reduction in a mass of glass used to make the glass pharmaceutical vial of greater than or equal to 5%.

6. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of energy used to convert the glass pharmaceutical vial from stock glass tubing of greater than or equal to 5%.

7. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of CO 2 emitted to produce the glass pharmaceutical vial of greater than or equal to 5%.

8. The glass pharmaceutical vial of claim 1 , wherein the sidewall of the glass pharmaceutical vial having an average wall thickness T i that is less than or equal to 0.85*s 1 correlates to a reduction in an amount of energy used to separate the glass pharmaceutical vial from stock glass tubing of greater than or equal to 20%.

9. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial has a Type 1 chemical durability according to USP <660>.

10. The glass pharmaceutical vial of claim 1 , further comprising an external organic coating is an organic coating having a thickness greater than or equal to 20 nm and less than or equal to 40 nm.

11. The glass pharmaceutical vial of claim 1 , wherein

the glass pharmaceutical vial comprises an external organic coating and has an intervention rate, according to an Accumulator Table Experiment, of less than or equal to 0.90×R I , wherein R I is an intervention rate of the glass vial of size designation X as defined by ISO 8362-1:2018.

12. The glass pharmaceutical vial of claim 11 , wherein the glass pharmaceutical vial has a jam rate, according to the Accumulator Table Experiment, of less than or equal to 3 jams/minute.

13. The glass pharmaceutical vial of claim 11 , wherein the glass pharmaceutical vial has an intervention rate, according to the Accumulator Table Experiment, of less than or equal to 50 events/hour.

14. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a compliance factor of at least 1.75, as determined in accordance with a Vial Compliance Test.

15. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a Dynamic Impact Factor of less than 0.9, as determined in accordance with a Dynamic Impact Test.

16. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises a FWHM Factor of at least 1.2, as determined in accordance with a Dynamic Impact Test.

17. The glass pharmaceutical vial of claim 1 , wherein the glass pharmaceutical vial comprises:

a Dynamic Impact Factor of less than 0.9, as determined in accordance with a Dynamic Impact Test; and

a FWHM Factor of at least 1.2, as determined in accordance with the Dynamic Impact Test.

18. The glass pharmaceutical vial of claim 10 , wherein the external organic coating is an organic coating having a thickness greater than or equal to 20 nm and less than or equal to 40 nm.

19. The glass pharmaceutical vial of claim 11 , wherein the neck has a neck outside diameter N OD such that the neck outside diameter N OD is smaller than a neck outside diameter of the glass vial of size designation X as defined by ISO 8362-1:2018.

20. The glass pharmaceutical vial of claim 18 , wherein the neck outside diameter Non of the glass pharmaceutical vial is at least 0.4 mm less than the neck outside diameter of the glass vial of size designation X as defined by ISO 8362-1:2018.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2024
From: AALDENBERG, JARED SEAMAN; ALLINGTON, ERIC LEWIS; CHAPMAN, CHRISTY LYNN; CIMO, PATRICK JOSEPH; DEMARTINO, STEVEN EDWARD; GOMEZ-MOWER, SINUE; JIANG, WEIRONG; MATUSICK, JOSEPH MICHAEL; MCCARTHY, CHRISTIE LEIGH; MCNELIS, KEVIN PATRICK; MUSK, BRYAN JAMES; NONI, DOUGLAS MILES, JR.; O'MALLEY, CONNOR THOMAS; PEANASKY, JOHN STEPHEN; POLASANI, SHIVANI RAO; RUOTOLO, MICHAEL CLEMENT, JR.; SARAFIAN, ADAM ROBERT; SCHAUT, ROBERT ANTHONY; TREMPER, AMBER LEIGH; WAIGHT, KRISTEN DAE; WEBB, JAMES ERNEST
To: CORNING INCORPORATED
Reel/Frame 068548/0519 →
Continuity (4)
Continuation 17957964 · Sep 30, 2022
Provisional Application 63277488 · Nov 9, 2021
Provisional Application 63250497 · Sep 30, 2021
Related Publication 20240366474A1 · Nov 7, 2024
References Cited (73)
US 4244478A · Handman · 1981 [cited by applicant]
US 4664277A · Connor · 1987 [cited by applicant]
US 5064083A · Alexander et al. · 1991 [cited by applicant]
US 5772057A · Finneran · 1998 [cited by applicant]
US 6090093A · Thibault et al. · 2000 [cited by applicant]
US 6645635B2 · Muraki · 2003 [cited by applicant]
US 7282269B2 · Wang et al. · 2007 [cited by applicant]
US 8092878B2 · Miller et al. · 2012 [cited by applicant]
US 8497004B2 · Davis et al. · 2013 [cited by applicant]
US 8544665B2 · Bogle et al. · 2013 [cited by applicant]
US 8551898B2 · Danielson et al. · 2013 [cited by applicant]
US 8684206B2 · Kawachi · 2014 [cited by applicant]
US 9080044B2 · Muto · 2015 [cited by applicant]
US 10737973B2 · Bayne · 2020 [cited by examiner]
US 10780021B2 · Weikart et al. · 2020 [cited by applicant]
US 11168019B2 · Schaut et al. · 2021 [cited by applicant]
US 12076296B2 · DeMartino · 2024 [cited by examiner]
US 20020023409A1 · Py · 2002 [cited by applicant]
US 20020166326A1 · Giesy et al. · 2002 [cited by applicant]
US 20030177629A1 · Thibault et al. · 2003 [cited by applicant]
US 20070246468A1 · Miller et al. · 2007 [cited by applicant]
US 20090145427A1 · Groeger et al. · 2009 [cited by applicant]
US 20100273049A1 · Vidal et al. · 2010 [cited by applicant]
US 20120148770A1 · Rong et al. · 2012 [cited by applicant]
US 20140151370A1 · Chang · 2014 [cited by examiner]
US 20150211950A1 · Eckhoff et al. · 2015 [cited by applicant]
US 20150320641A1 · Fangrow · 2015 [cited by applicant]
US 20150344557A1 · Malik et al. · 2015 [cited by applicant]
US 20160009460A1 · Fournier et al. · 2016 [cited by applicant]
US 20160075485A1 · Masuyama et al. · 2016 [cited by applicant]
US 20160145150A1 · Bookbinder et al. · 2016 [cited by applicant]
US 20160324723A1 · Lippert et al. · 2016 [cited by applicant]
US 20180257975A1 · Kimura et al. · 2018 [cited by applicant]
US 20200071222A1 · Higginbottom Dahlman et al. · 2020 [cited by applicant]
US 20200146280A1 · Silverman et al. · 2020 [cited by applicant]
US 20200156991A1 · Allington et al. · 2020 [cited by applicant]
US 20200271541A1 · Mathaes et al. · 2020 [cited by applicant]
US 20200399165A1 · Frost · 2020 [cited by examiner]
US 20210002016A1 · Langsdore et al. · 2021 [cited by applicant]
US 20210212893A1 · Christie et al. · 2021 [cited by applicant]
US 20220168185A1 · Redkar et al. · 2022 [cited by applicant]
US 20220339067A1 · Christie et al. · 2022 [cited by applicant]
US 20220387257A1 · Reisse et al. · 2022 [cited by applicant]
US 20230087680A1 · Hoff et al. · 2023 [cited by applicant]
US 20230112425A1 · Christie et al. · 2023 [cited by applicant]
US 20230174410A1 · Gross et al. · 2023 [cited by applicant]
US 20230233408A1 · McCarthy et al. · 2023 [cited by applicant]
US 20230277415A1 · Bucholtz et al. · 2023 [cited by applicant]
CA 3138450A1 · 2020 [cited by applicant]
EP 3708137A1 · 2020 [cited by applicant]
JP 10179688A · 1998 [cited by applicant]
JP 2010209157A · 2010 [cited by applicant]
WO 2013034594A1 · 2013 [cited by applicant]
WO 2020112634A1 · 2020 [cited by applicant]
WO 2020231474A2 · 2020 [cited by applicant]
WO 2021042090A2 · 2021 [cited by applicant]
WO 2021162984A1 · 2021 [cited by applicant]
WO 2022020120A1 · 2022 [cited by applicant]
Hagart-Alexander, C., Temperature Measurement, 2010, Elsevier Inc., pp. 269-271 (Year: 2010). [cited by applicant]
“Simply Stronger Vials”, SGD Pharma Product Brochure, pp. 1-4, 2019. [cited by applicant]
International Search Report relating to PCT/US2022/077413 filed Sep. 30, 2022; dated Feb. 8, 2023. [cited by applicant]
U.S. Non-Final Office Action dated Jul. 6, 2023, pertaining to U.S. Appl. No. 18/310,944, 19 pgs. [cited by applicant]
U.S. Non-Final Office Action dated Feb. 27, 2024, pertaining to U.S. Appl. No. 18/310,956, 9 pgs. [cited by applicant]
Amrhein et al., Gerresheimer, “The lighter way of glass packing: How to reduce weight to save material and energy”. pp. 1-12. [cited by applicant]
“Molding Innovation into healthcare packaging”, Retrieved from: https://www.araymond-life.com/en, ARaymond Life + Schott plastic cap for cold storage CCI presentation at PDA Conference (Mar. 2020), 4 pages. [cited by applicant]
Brigitte Zuleger et al., Container/Closure Integrity Testing and the Identification of a Suitable Vial/Stopper Combination for Low-Temperature Storage at -80°C, 2012, PDA JPST, vol. 66, Abstract (Year: 2012). [cited by applicant]
Ethylene-Propylene Rubbers & Elastomers, Apr. 20, 2012, International Institute of Synthetic Rubber Producers, Inc. (Year: 2012). [cited by applicant]
U.S. Notice of Allowance dated Feb. 15, 2024, pertaining to U.S. Appl. No. 18/310,951, 6 pgs. [cited by applicant]
Iacocca, R., “Primary container design for drug substance and drug substance at Cryo-and cold temperatures,” Presented at the 2019 PDA Europe Parenteral Packaging, Venice, Italy, Mar. 19, 2019. pp. 1-22. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority; PCT/US22/41311; mailed on Nov. 22, 2022, 14 pages; European Patent Office. [cited by applicant]
Nieto, A. and H. Roehl (2018). “Sealing Behaviour of Container Closure Systems under Frozen Storage Conditions: Nonlinear Finite Element Simulation of Serum Rubber Stoppers.” PDA J Pharm Sci and Tech (2018), 72(4): 367-… [cited by applicant]
Sircoulomb et al., “Cryogenic Storage Challenges for Container-Closure Systems,” Mar. 25, 2020, available at https://www.pda.org/pda-leller-portal/home/full-article/cryogenic—storage-challenges-for-container-closure-sys… [cited by applicant]
US Non-Final Office Action dated Jul. 6, 2023, pertaining to U.S. Appl. No. 18/310,964, 23 pgs. [cited by applicant]